Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine
Waage, A.; Hammerstrøm, J.; Lødemel, B.; Hoff, J.E.; Langtind, J.
Tidsskrift for den Norske Laegeforening Tidsskrift for Praktisk Medicin Ny Raekke 106(6): 496-497
1986
ISSN/ISBN: 0029-2001 PMID: 3457484 Document Number: 283319
Document emailed within 1 workday
Related Documents
Hamaoka, R.; Jozaki, K.; Amano, T.; Itoh, H.; Imai, Y.; Nishikawa, M.; Kurokawa, M.; Yonezawa, T.; Chinen, Y. 1995: Low-dose cytarabine ocfosfate therapy in an elderly acute myelogenous leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 819-822Decker, R.W.; Ho, W.G.; Champlin, R.E. 1987: Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia Cancer Treatment Reports 71(9): 881-882
Matthews, D.C. 1998: Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome Leukemia 12(Suppl 1): S33-S36
Bassan, R.; Raimondi, R.; Lerede, T.; D'emilio, A.; Buelli, M.; Borleri, G.; Personeni, A.; Bellavita, P.; Rodeghiero, F.; Barbui, T. 1998: Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia Haematologica 83(7): 627-635
Hsu, H.C.; Chiu, C.F.; Tan, T.D.; Chau, W.K.; Tseng, C.S.; Ho, C.H. 1995: Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report Zhonghua Yi Xue Za Zhi 56(5): 305-311
Arai, T.; Narimiya, S.; Hayakawa, K.; Takaya, T.; Toshima, S.; Araki, M.; Uchida, A.; Yoshimi, N.; Shibuya, C.; Yasuda, Y. 1994: Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(7): 1085-1088
Yoshida, M.; Tsunoda, S.; Akutsu, M.; Furukawa, Y.; Takeda, K.; Akashi, M.; Komatsu, N.; Muroi, K.; Ikeda, K.; Ohsaka, A. 1987: The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(4): 1057-1062
Shlapak, D.; Kerisit, K.; Lin, C.; Wang, A.; Stumpf, B. 2013: Resident rounds. Part III: Neutrophilic eccrine hidradenitis in the setting of acute myelogenous leukemia treated with cytarabine Journal of drugs in dermatology: JDD 12(2): 231-232
Nishi, T.; Funasako, M.; Hata, N.; Andoh, K.; Itoh, Y.; Ono, H.; Itoh, K.; Sato, Y.; Sato, H.; Taniji, M.; Nakai, S.; Ueda, A.; Fujimoto, H.; Ohata, M. 1996: Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(10): 1331-1334
Okamoto, T.; Kanamaru, A.; Shimazaki, C.; Motoji, T.; Takemoto, Y.; Takahashi, M.; Fukushima, T.; Takeshita, A.; Kusumoto, G.S.; Kishimoto, Y.; Yorimitsu, S.; Tsukuda, K.; Uike, N.; Arima, N.; Ohno, R. 2000: Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis International Journal of Hematology 72(2): 200-205
Archimbaud, E.; Fenaux, P.; Reiffers, J.; Cordonnier, C.; Leblond, V.; Travade, P.; Troussard, X.; Tilly, H.; Auzanneau, G.; Marie, J.P. 1993: Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia Leukemia 7(3): 372-377
Gerhartz, H.H.; Visani, G.; Delmer, A.; Zwierzina, H.; Ribeiro, M.; Jacobs, A.; Marcus, R.; Baumelou, M.; Fière, D.; Labar, B. 1989: Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group Bone Marrow Transplantation 4(Suppl 3): 36-37
Cortes, J.E.; Kantarjian, H.; O'Brien, S.; Keating, M.; Pierce, S.; Freireich, E.J.; Estey, E. 1995: Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes Leukemia 9(1): 115-117
Arlin, Z.A.; Feldman, E.J.; Finger, L.R.; Ahmed, T.; Mittelman, A.; Cook, P.; Puccio, C.; Baskind, P.; Arnold, P.; Razis, E.D. 1991: Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia Leukemia 5(8): 712-714
Hoppe, R.T. 1992: Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease Leukemia 6(Suppl 4): 155-157
Ghaddar, H.M.; Plunkett, W.; Kantarjian, H.M.; Pierce, S.; Freireich, E.J.; Keating, M.J.; Estey, E.H. 1994: Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside Leukemia 8(8): 1269-1274
Elias, L. 1988: The basis for treatment of myelodysplastic syndrome and acute nonlymphoblastic leukemia with biologic agents Leukemia 2(6): 400-402
Plunkett, W.; Nowak, B.; Keating, M.J. 1987: Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy Cancer Treatment Reports 71(5): 479-483
Sutoh, H.; Yamauchi, T.; Gotoh, N.; Sugiyama, M.; Ueda, T. 2003: Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia Anticancer Research 23(6d): 5037-5042
Miyawaki, S.; Mizoguchi, H.; Tomonaga, M.; Kanamaru, A.; Tsukagoshi, S.; Nakamura, T.; Ohashi, Y.; Yoshida, S.; Ohno, R. 1998: A phase Ii study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(14): 2229-2242